Advertisement

Gastric Bypass pp 453-458 | Cite as

Gastric Bypass for Type 2 Diabetes Mellitus on BMI < 35

  • Admar Concon-Filho
  • Andre Fernandes Teixeira
  • Eduardo Grecco
  • Luiz Gustavo Quadros
  • Manoel Galvão Neto
  • Thiago Ferreira de Souza
Chapter
  • 34 Downloads

Abstract

Bariatric surgery can cause resolution of the clinical manifestations of type 2 diabetes, as well as improvement. There are data that do not allow the assumption of an absolute cause-and-effect relationship between body weight and type 2 diabetes. The primary risk factor for type 2 diabetes is obesity, and 90% of all patients with type 2 diabetes are overweight or obese. Metabolic surgery is the only diabetes treatment proven to result in long-term remission in 23–60% of patients depending upon preoperative duration of diabetes and disease severity. Reported an overall type 2 DM remission rate of 78% after bariatric surgery with 1–3 years of follow-up. Surgery should also be considered for patients with type 2 DM and BMI 30.0–34.9 kg/m2 if hyperglycemia is inadequately controlled despite optimal treatment with either oral or injectable medications.

Keywords

Obesity Bariatric surgery Metabolic surgery BMI Type 2 Diabetes BMI < 35 

References

  1. 1.
    Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery:systematic review and meta-analysis. Am J Med. 2009;122(3)CrossRefGoogle Scholar
  2. 2.
    Parikh M, Chung M, Sheth S, McMacken M, Zahra T, Saunders JK, Ude-Welcome A, Ogedegbe G, Schmidt AM, Pachter L. Randomized pilot trial of bariatric surgery vs. intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014;260(4):617–24.CrossRefGoogle Scholar
  3. 3.
    Schauer PR, Hanipah ZN, Rubino F. Metabolic surgery for treating type 2 diabetes mellitus: now supported by the world’s leading diabetes organizations. Cleve Clin J Med. 2017;84CrossRefGoogle Scholar
  4. 4.
    Dixon JB, Le Roux C, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet. 2012;379(9833):2213.CrossRefGoogle Scholar
  5. 5.
    Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable gastric banding and conventional therapy for type 2 diabetes : a randomized controlled trial. JAMA. 2008;299(3)., (Reprinted).Google Scholar
  6. 6.
    Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, Hamdy O, Clancy K, Lautz D, Vernon A, Goldfine AB. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab. 2015;100(7):2546–56.CrossRefGoogle Scholar
  7. 7.
    Mingrone G, Panunzi S, Gaetano AD, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):932.CrossRefGoogle Scholar
  8. 8.
    Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N Engl J Med. 2017;376; 7 nejm.org February 16.CrossRefGoogle Scholar
  9. 9.
    Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, Bock SN, Landers JT, Kratz M, Foster-Schubert KE, Flum DR. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59:945–53.CrossRefGoogle Scholar
  10. 10.
    Abbatini F, Capoccia D, Casella G, Coccia F, Leonetti F, Basso N. Type 2 diabetes in obese patients with body mass index of 30–35 kg/m2: sleeve gastrectomy versus medical treatment. SOARD. 2012;8(1):20–4.Google Scholar
  11. 11.
    Du X, Zhou HX, Zhang SQ, Tian HM, Zhou ZG, Zhong CZ. A comparative study of the metabolic effects of LSG and LRYGB in Chinese diabetes patients with BMI<35 kg/m2. SOARD. 2017;13(2):189–97.Google Scholar
  12. 12.
    Malapan K, Goel R, Tai CM, Kao YH, Chang PC, Huang CK. Laparoscopic Roux-en-Y gastric bypass for nonobese type II diabetes mellitus in Asian patients. SORD. 2014;10(5):840–1.Google Scholar
  13. 13.
    Horwitz D, Saunders JK, Ude-Welcome A, Schmidt AM, Dunn V, Pachter L, Parikh M. Three-year follow-up comparing metabolic surgery versus medical weight management in patients with type 2 diabetes and BMI 30–35. The role of sRAGE biomarker as predictor of satisfactory outcomes. SORD. 2016;12(7):1342.Google Scholar
  14. 14.
    Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB, InabnetIII WB, Jeffery RW, Chong K, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Olofson AE, Korner J. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3(6):394–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Admar Concon-Filho
    • 1
    • 2
    • 3
  • Andre Fernandes Teixeira
    • 4
  • Eduardo Grecco
    • 5
  • Luiz Gustavo Quadros
    • 6
  • Manoel Galvão Neto
    • 1
    • 7
    • 8
  • Thiago Ferreira de Souza
    • 1
    • 5
    • 8
    • 9
  1. 1.Faculty of Medicine of ABC – FMABCSanto AndréBrazil
  2. 2.Concon ClinicValinhosBrazil
  3. 3.Galileo Hospital and MaternityValinhosBrazil
  4. 4.Bariatric and Laparoscopy Center, Orlando HealthOrlandoUSA
  5. 5.ABC Medical School (FMABC)São PauloBrazil
  6. 6.Department of Bariatric endoscopyKaiser day hosptialSão José do Rio PretoBrazil
  7. 7.Florida International University – FIUMiamiUSA
  8. 8.EndoVitta InstituteSão PauloBrazil
  9. 9.University of São Paulo – USPSão PauloBrazil

Personalised recommendations